Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease

References

• Birkmayer W, Hornykiewicz O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr. 1961 Nov 10;73:787–788.
   PubMedGoogle Scholar
• Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018 Aug;33(8):1248–1266.
   PubMed Web of Science ®Google Scholar
• Widnell K. Pathophysiology of motor fluctuations in Parkinson’s disease. Mov Disord. 2005;20(11):S17–22. doi:10.1002/mds.20459.
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lennernas H, Gomes-Trolin C, et al. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson’s disease on individual drug combinations. Clin Neuropharmacol. 2002 Mar;25(2):89–96.
   PubMed Web of Science ®Google Scholar
• Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease ropinirole study group. Neurology. 1998 Oct;51(4):1057–1062.
   PubMed Web of Science ®Google Scholar
• Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007 Sep;13:S13–7. doi: 10.1016/j.parkreldis.2007.06.005
   PubMed Web of Science ®Google Scholar
• Adler CH. Relevance of motor complications in Parkinson’s disease. Neurology. 2002 Feb 26;58(4 Suppl 1):S51–6. doi: 10.1212/WNL.58.suppl_1.S51
   PubMed Web of Science ®Google Scholar
• Chou KL, Stacy M, Simuni T, et al. The spectrum of “off” in Parkinson’s disease: what have we learned over 40 years? Parkinsonism Relat Disord. 2018 Jun;51:9–16.
   PubMed Web of Science ®Google Scholar
• Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord. 2015 Jan;30(1):80–89. doi: 10.1002/mds.26125
   PubMed Web of Science ®Google Scholar
• Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010 Nov;257(Suppl 2):S253–61. doi: 10.1007/s00415-010-5728-8
   PubMed Web of Science ®Google Scholar
• Calabresi P, Di Filippo M, Ghiglieri V, et al. Levodopa-induced dyskinesias in patients with Parkinson’s disease: filling the bench-to-bedside gap. Lancet Neurol. 2010 Nov;9(11):1106–1117.
   PubMed Web of Science ®Google Scholar
• SINEMET® (Carbidopa-Levodopa) Tablets [prescribing information]. Princeton, NJ: Merck & Co., Inc. 2014. [cited 2023 Feb 10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/017555s069lbl.pdf
   Google Scholar
• DHIVY (carbidopa and levodopa) tablets [prescribing information]. Washington, DC: Riverside Pharmacy Corporation. 2021. [cited 2023 Mar 21]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214869s000lbl.pdf
   Google Scholar
• PARCOPA TM (carbidopa-levodopa orally disintegrating tablets) [prescribing information]. Eden Prairie, MN: Schwarz Pharma. 2007. [cited 2023 Feb 6]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/076699_S000_PARCOPA_PRNTLBL.pdf
   Google Scholar
• SINEMET® CR (carbidopa levodopa) Sustained-Release Tablets [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc. 2014. [cited 2023 Feb 10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019856s016s024s028lbl.pdf
   Google Scholar
• DUOPA®(carbidopa and levodopa) enteral suspension [prescribing information]. North Chicago, IL: AbbVie Inc. 2022. [cited 2023 Feb 6]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203952s004lbl.pdf
   Google Scholar
• Rytary (carbidopa and levodopa) extended-release capsules [prescribing information]. Hayward, CA: Impax Pharmaceuticals. 2019. [cited 2023 Feb 10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203312s000lbl.pdf
   Google Scholar
• INBRIJA™ (levodopa inhalation powder) [prescribing information]. Ardsley, NY: Acorda Therapeutics, Inc. 2022. [cited 2023 Feb 6]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209184s000lbl.pdf
   Google Scholar
• Markham CH, Treciokas LJ, Diamond SG. Parkinson’s disease and levodopa. A five-year follow-up and review. West J Med. 1974 Sep;121(3):188–206.
   PubMedGoogle Scholar
• Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol. 1997;37(1):23–27. DOI:10.1159/000117399
   PubMed Web of Science ®Google Scholar
• Ondo WG, Shinawi L, Moore S. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: a single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. Mov Disord. 2010 Dec 15;25(16):2724–2727. doi: 10.1002/mds.23158
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013 Apr;12(4):346–356.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Lyons KE, Hauser RA, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s disease. Parkinsonism Relat Disord. 2014 Feb;20(2):142–148.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Hauser RA, Grosset DG, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson’s disease. Mov Disord. 2016 Sep;31(9):1356–1365.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Pahwa R, Sedkov A, et al. Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson’s Disease. J Aerosol Med Pulm Drug Deliv. 2018 Jun;31(3):155–161.
   PubMed Web of Science ®Google Scholar
• Grosset D, Dhall R, Gurevich T, et al. Long-term Efficacy of Inhaled Levodopa in Parkinson’s Disease Subjects with Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.008). Neurology. 2018;90(15 Supplement):S26.008.
   Google Scholar
• Grosset D, Dhall R, Gurevich T, et al. Long-Term Pulmonary Safety of Inhaled Levodopa in Parkinson’s Disease Subjects with Motor Fluctuations: a Phase 3 Open-Label Randomized Study (S26.006). Neurology. 2018;90(15 Supplement):S26.006.
   Google Scholar
• LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019 Feb;18(2):145–154.
   PubMed Web of Science ®Google Scholar
• Rispoli V, Simioni V, Capone JG, et al. Peripheral neuropathy in 30 duodopa patients with vitamins B supplementation. Acta Neurol Scand. 2017 Dec;136(6):660–667.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Boyd JT, Fung VSC, et al. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease. Mov Disord. 2018 Jul;33(6):928–936.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014 Feb;13(2):141–149.
   PubMed Web of Science ®Google Scholar
• Isaacson SH, Pagan FL, Lew MF, et al. Should “on-demand” treatments for Parkinson’s disease off episodes be used earlier? Clin Park Relat Disord. 2022;7:100161. DOI:10.1016/j.prdoa.2022.100161
   PubMedGoogle Scholar
• Fabbri M, Barbosa R, Rascol O. Off-time Treatment Options for Parkinson’s Disease. Neurol Ther. 2023 Jan 12;12(2):391–424. doi: 10.1007/s40120-022-00435-8
   PubMed Web of Science ®Google Scholar
• Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997 Jul;49(1):162–168. doi: 10.1212/WNL.49.1.162
   PubMed Web of Science ®Google Scholar
• Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson’s disease. Clin Neuropharmacol. 1995 Aug;18(4):338–347.
   PubMed Web of Science ®Google Scholar
• Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson’s disease. J Neural Transm Suppl. 1995;45:225–230.
   PubMedGoogle Scholar
• Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study Group. Neurology. 1997 Oct;49(4):1060–1065. doi: 10.1212/WNL.49.4.1060
   PubMed Web of Science ®Google Scholar
• Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):436–441. doi: 10.1136/jnnp.66.4.436
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov Disord. 2003 Oct;18(10):1149–1156.
   PubMed Web of Science ®Google Scholar
• Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord. 2005 May;20(5):602–610.
   PubMed Web of Science ®Google Scholar
• Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007 Jun;6(6):513–520.
   PubMed Web of Science ®Google Scholar
• Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010 Jul;7(7):CD007166.
   Google Scholar
• Schapira AH, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011 Aug 23;77(8):767–774. doi:10.1212/WNL.0b013e31822affdb.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Schapira AH, Barone P, et al. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson’s disease. Eur J Neurol. 2014 May;21(5):736–743.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Barone P, Hauser RA, et al. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson’s disease. Eur J Neurol. 2013 Jan;20(1):180–187.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007 Apr 3;68(14):1108–1115. doi:10.1212/01.wnl.0000258660.74391.c1.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R, et al. Advanced Parkinson disease treated with rotigotine transdermal system: pREFER Study. Neurology. 2007 Apr 17;68(16):1262–1267. DOI:10.1212/01.wnl.0000259516.61938.bb
   PubMed Web of Science ®Google Scholar
• Dewey, RB Jr., Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001 Sep;58(9):1385–1392. doi:10.1001/archneur.58.9.1385.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Factor SA, Espay AJ, et al. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020 Feb;19(2):135–144.
   PubMed Web of Science ®Google Scholar
• Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004 Apr;19(4):426–432.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Fox SH, Hauser RA, et al. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients with Parkinson Disease and Motor Fluctuations: a Randomized Clinical Trial. JAMA Neurol. 2017 Feb 1;74(2):216–224. doi:10.1001/jamaneurol.2016.4467.
   PubMed Web of Science ®Google Scholar
• Group PS. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005 Feb;62(2):241–248.
   PubMedGoogle Scholar
• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005 Mar 12-18;365(9463):947–954. doi:10.1016/S0140-6736(05)71083-7.
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014 Feb;29(2):229–237.
   PubMed Web of Science ®Google Scholar
• Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology. 1997 Oct;49(4):1066–1071.
   PubMed Web of Science ®Google Scholar
• Group PS. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol. 1997 Nov;42(5):747–755. doi:10.1002/ana.410420511
   PubMed Web of Science ®Google Scholar
• Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):421–428.
   PubMed Web of Science ®Google Scholar
• Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations nomecomt study group. Neurology. 1998 Nov;51(5):1309–1314.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Kondo T, Japanese Istradefylline Study G. Adenosine A2A receptor antagonist istradefylline reduces daily off time in Parkinson’s disease. Mov Disord. 2013 Jul;28(8):1138–1141. doi: 10.1002/mds.25418
   PubMed Web of Science ®Google Scholar
• Lees AJ, Ferreira J, Rascol O, et al. Opicapone as Adjunct to Levodopa Therapy in Patients with Parkinson Disease and Motor Fluctuations: a Randomized Clinical Trial. JAMA Neurol. 2017 Feb 1;74(2):197–206. doi:10.1001/jamaneurol.2016.4703.
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154–165.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Tanner CM, Hauser RA, et al. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): a Randomized Clinical Trial. JAMA Neurol. 2017 Aug 1;74(8):941–949. doi:10.1001/jamaneurol.2017.0943
   PubMed Web of Science ®Google Scholar
• Oertel W, Eggert K, Pahwa R, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord. 2017 Dec;32(12):1701–1709. doi:10.1002/mds.27131.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008 Mar;63(3):295–302.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Hattori N, Fernandez H, et al. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: a Pooled Analysis of 8 Phase 2b/3 Trials. J Parkinsons Dis. 2021;11(4):1663–1675. doi: 10.3233/JPD-212672
   PubMedGoogle Scholar
• Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord. 2008 Nov 15;23(15):2177–2185. DOI:10.1002/mds.22095
   PubMed Web of Science ®Google Scholar
• Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clin Neuropharmacol. 1988 Feb;11(1):45–55.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Hasegawa K, Kondo T, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord. 2010 Jul 30;25(10):1437–1443. doi:10.1002/mds.23107
   PubMed Web of Science ®Google Scholar
• MIRAPEX® (pramipexole dihydrochloride) tablets: Boehringer Ingelheim Pharmaceuticals, Inc; 2018 [February 26, 2023]; Prescribing Information]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020667s036lbl.pdf
   Google Scholar
• Foley P, Gerlach M, Double KL, et al. Dopamine receptor agonists in the therapy of Parkinson’s disease. J Neural Transm (Vienna). 2004 Oct;111(10–11):1375–1446.
   PubMed Web of Science ®Google Scholar
• Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson’s disease. Clin Neuropharmacol. 1998 May;21(3):141–151.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. A promising new technology for Parkinson’s disease. Neurology. 2005 Jul 26;65(2 Suppl 1):S6–10. doi: 10.1212/WNL.65.2_suppl_1.S6
   PubMed Web of Science ®Google Scholar
• MIRAPEX ER® (pramipexole dihydrochloride) extended-release tablets: Boehringer Ingelheim Pharmaceuticals, Inc; 2018 [February 24, 2023]; Prescribing Information]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022421s017lbl.pdf
   Google Scholar
• Jenner P, Konen-Bergmann M, Schepers C, et al. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther. 2009 Nov;31(11):2698–2711.
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484–1491. DOI:10.1056/NEJM200005183422004
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Rossi C, Del Prete E, et al. A review of adverse events linked to dopamine agonists in the treatment of Parkinson’s disease. Expert Opin Drug Saf. 2016;15(2):181–198. DOI:10.1517/14740338.2016.1130128
   PubMed Web of Science ®Google Scholar
• Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol. 2009 Oct;8(10):929–937.
   PubMed Web of Science ®Google Scholar
• Voon V, Napier TC, Frank MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: an update. Lancet Neurol. 2017 Mar;16(3):238–250.
   PubMed Web of Science ®Google Scholar
• Zhou CQ, Lou JH, Zhang YP, et al. Long-acting versus standard non-ergot dopamine agonists in Parkinson’s disease: a meta-analysis of randomized controlled trials. CNS Neurosci Ther. 2014 Apr;20(4):368–376.
   PubMed Web of Science ®Google Scholar
• Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology. 1997 Jul;49(1 Suppl 1):S58–62. doi: 10.1212/WNL.49.1_Suppl_1.S58
   PubMed Web of Science ®Google Scholar
• Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology. 1997 Aug;49(2):393–399.
   PubMed Web of Science ®Google Scholar
• Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol. 1996 Jun;19(3):234–245.
   PubMed Web of Science ®Google Scholar
• Brunt ER, Brooks DJ, Korczyn AD, et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson’s disease not optimally controlled by L-dopa. J Neural Transm (Vienna). 2002 Apr;109(4):489–502.
   PubMed Web of Science ®Google Scholar
• Im JH, Ha JH, Cho IS, et al. Ropinirole as an adjunct to levodopa in the treatment of Parkinson’s disease: a 16-week bromocriptine controlled study. J Neurol. 2003 Jan;250(1):90–96.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Abe T, Hasegawa K, et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson’s disease: sTRONG study. Mov Disord. 2007 Oct 15;22(13):1860–1865. DOI:10.1002/mds.21313
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Chriscoe S, Jimenez T, et al. A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson’s disease. Neurodegener Dis Manag. 2017 Feb;7(1):61–72.
   PubMedGoogle Scholar
• REQUIP XL (ropinirole) extended-release tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2021. [cited 2023 Feb 24]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022008s003s004s007s008lbledt.pdf
   Google Scholar
• Tompson D, Oliver-Willwong R. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson’s disease. Clin Neuropharmacol. 2009 May;32(3):140–148. doi: 10.1097/WNF.0b013e318176c505
   PubMed Web of Science ®Google Scholar
• REQUIP® (ropinirole hydrochloride) Tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2007. [cited 2023 Feb 23]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020658s018s020s021lbl.pdf
   Google Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010 May;67(5):589–595.
   PubMed Web of Science ®Google Scholar
• Wood M, Dubois V, Scheller D, et al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015 Feb;172(4):1124–1135.
   PubMed Web of Science ®Google Scholar
• Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73–86.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Boroojerdi B, Surmann E, et al. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J Neural Transm (Vienna). 2013 Jul;120(7):1069–1081.
   PubMed Web of Science ®Google Scholar
• NEUPRO (rotigotine transdermal system) [prescribing information]. Smyrna, GA: UCB, Inc. 2021. [cited 2023 Feb 10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s001lbl.pdf
   Google Scholar
• Gupta HV, Lyons KE, Pahwa R. Old Drugs, New Delivery Systems in Parkinson’s Disease. Drugs Aging. 2019 Sep;36(9):807–821. doi: 10.1007/s40266-019-00682-9
   PubMed Web of Science ®Google Scholar
• Reynolds NA, Wellington K, Easthope SE. Rotigotine: in Parkinson’s disease. CNS Drugs. 2005;19(11):973–981. doi:10.2165/00023210-200519110-00006.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM, Dashtipour K, et al. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson’s disease. Pharmacotherapy. 2009 Dec;29(12):1452–1467.
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs Aging. 2004;21(11):687–709. doi:10.2165/00002512-200421110-00001.
   PubMed Web of Science ®Google Scholar
• Clinical Review Report: Apomorphine (Movapo):Paladin Labs, Inc. Indication: The acute, intermittent treatment of hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced Parkinson’s disease. Ottawa, Ontario: Canadian Agency for Drugs and Technologies in Health; 2018.
   Google Scholar
• Pfeiffer RF, Gutmann L, Hull KL Jr., et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2007 Mar;13(2):93–100.
   PubMed Web of Science ®Google Scholar
• Pahwa R, Koller WC, Trosch RM, et al. Subcutaneous apomorphine in patients with advanced Parkinson’s disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci. 2007 Jul 15;258(1–2):137–143. DOI:10.1016/j.jns.2007.03.013
   PubMed Web of Science ®Google Scholar
• APOKYN® (apomorphine hydrochloride injection) [prescribing information]. Louisville, KY: US WorldMeds, LLC; 2016. Accessed 27 February 2023. : https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021264s014lbl.pdf
   Google Scholar
• Isaacson SH, Dewey RB Jr., Pahwa R, et al. How to manage the initiation of apomorphine therapy without antiemetic pretreatment: a review of the literature. Clin Park Relat Disord. 2023;8:100174. DOI:10.1016/j.prdoa.2022.100174
   PubMedGoogle Scholar
• Ondo WG, Hunter C, Ferrara JM, et al. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord. 2012 Jun;18(5):619–622.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Isaacson S, Clinch T, et al. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord. 2014 Nov;20(11):1171–1176.
   PubMed Web of Science ®Google Scholar
• Hattori N, Nomoto M, Study G. Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson’s disease. Parkinsonism Relat Disord. 2014 Aug;20(8):819–823. doi: 10.1016/j.parkreldis.2014.04.008
   PubMed Web of Science ®Google Scholar
• Deffond D, Durif F, Tournilhac M. Apomorphine in treatment of Parkinson’s disease: comparison between subcutaneous and sublingual routes. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):101–103. doi: 10.1136/jnnp.56.1.101
   PubMed Web of Science ®Google Scholar
• Lees AJ, Montastruc JL, Turjanski N, et al. Sublingual apomorphine and Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1989 Dec;52(12):1440.
   PubMed Web of Science ®Google Scholar
• Hauser RA, Olanow CW, Dzyngel B, et al. Sublingual apomorphine (APL-130277) for the acute conversion of off to on in Parkinson’s disease. Mov Disord. 2016 Sep;31(9):1366–1372.
   PubMed Web of Science ®Google Scholar
• KYNMOBI TM (apomorphine hydrochloride) sublingual film [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2022. Accessed 27 February 2023.: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/210875Orig1s000lbl.pdf
   Google Scholar
• Robakis D, Fahn S. Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease. CNS Drugs. 2015 Jun;29(6):433–441. doi: 10.1007/s40263-015-0249-8
   PubMed Web of Science ®Google Scholar
• Jost WH. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease. J Neural Transm (Vienna). 2022 Jun;129(5–6):723–736. doi: 10.1007/s00702-022-02465-w
   PubMed Web of Science ®Google Scholar
• Tabi T, Vecsei L, Youdim MB, et al. Selegiline: a molecule with innovative potential. J Neural Transm (Vienna). 2020 May;127(5):831–842.
   PubMed Web of Science ®Google Scholar
• Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 May;51(5):604–612.
   PubMed Web of Science ®Google Scholar
• Eldepryl (Selegiline Hydrochloride) [prescribing information]. Tampa, FL: Somerset Pharmaceuticals, Inc; 2008. Accessed 30 January 2023. : https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020647s006s007lbl.pdf
   Google Scholar
• Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet. 1987 Sep;13(3):141–178. doi: 10.2165/00003088-198713030-00002
   PubMed Web of Science ®Google Scholar
• Lew MF. Selegiline orally disintegrating tablets for the treatment of Parkinson’s disease. Expert Rev Neurother. 2005 Nov;5(6):705–712. doi: 10.1586/14737175.5.6.705
   PubMedGoogle Scholar
• ZELAPAR® (Selegiline hydrochloride) orally disintegrating tablets [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; 2021. Accessed 30 January 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021479s010lbl.pdf
   Google Scholar
• AZILECT® (rasagiline mesylate) Tablets [prescribing information]. Kansas City, MO: Teva Neuroscience, Inc.; 2003. Accessed 10 February 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf
   Google Scholar
• Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004 Oct;24(10):1295–1305. doi: 10.1592/phco.24.14.1295.43156
   PubMed Web of Science ®Google Scholar
• Blair HA, Dhillon S. Safinamide: a Review in Parkinson’s Disease. CNS Drugs. 2017 Feb;31(2):169–176. doi: 10.1007/s40263-017-0408-1
   PubMed Web of Science ®Google Scholar
• Chase TN, Bibbiani F, Oh JD. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res. 2003;5(1–2):139–146. doi:10.1007/BF03033378.
   PubMed Web of Science ®Google Scholar
• Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson’s disease. Mol Neurobiol. 1996 Feb;12(1):73–94. doi: 10.1007/BF02740748
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Sardina M, Bonizzoni E. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson’s Disease Fluctuating Patients: post hoc Analyses of Studies 016 and SETTLE. J Parkinsons Dis. 2016;6(1):165–173. doi:10.3233/JPD-150700.
   PubMedGoogle Scholar
• XADAGO (safinamide) tablets [prescribing information]. Louisville, KY: US WorldMeds, LLC; 2021. Accessed 10 February 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207145lbl.pdf
   Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014 Sep;29(10):1273–1280.
   PubMed Web of Science ®Google Scholar
• Aboukarr A, Giudice M. Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors. Can J Hosp Pharm. 2018 May;71(3):196–207. doi: 10.4212/cjhp.v71i3.2586
   PubMed Web of Science ®Google Scholar
• Edinoff AN, Swinford CR, Odisho AS, et al. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. Health Psychol Res. 2022;10(4):39576. DOI:10.52965/001c.39576
   PubMed Web of Science ®Google Scholar
• Kurth MC, Adler CH. COMT inhibition: a new treatment strategy for Parkinson’s disease. Neurology. 1998 May;50(5 Suppl 5):S3–14. doi: 10.1212/WNL.50.5_Suppl_5.S3
   PubMedGoogle Scholar
• Artusi CA, Sarro L, Imbalzano G, et al. Safety and efficacy of tolcapone in Parkinson’s disease: systematic review. Eur J Clin Pharmacol. 2021 Jun;77(6):817–829.
   PubMed Web of Science ®Google Scholar
• TASMAR® (tolcapone) tablets [prescribing information]. Cost Mesa, CA: Valeant Pharmaceuticals International; 2006. Accessed 28 January 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020697s012lbl.pdf
   Google Scholar
• Sedek G, Jorga K, Schmitt M, et al. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol. 1997 Dec;20(6):531–541.
   PubMed Web of Science ®Google Scholar
• Fabbri M, Ferreira JJ, Rascol O. COMT Inhibitors in the Management of Parkinson’s Disease. CNS Drugs. 2022 Mar;36(3):261–282. doi: 10.1007/s40263-021-00888-9
   PubMed Web of Science ®Google Scholar
• Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol. 2000 Feb;57(2):263–267. doi: 10.1001/archneur.57.2.263
   PubMedGoogle Scholar
• Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007 Sep;30(5):287–294. doi: 10.1097/wnf.0b013e318038d2b6
   PubMed Web of Science ®Google Scholar
• Li J, Lou Z, Liu X, et al. Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson’s Disease with Motor Fluctuation: a Systematic Meta-Analysis. Eur Neurol. 2017;78(3–4):143–153. DOI:10.1159/000479555
   PubMed Web of Science ®Google Scholar
• COMTAN® (entacapone) Tablets [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; 2010. Accessed 28 January 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020796s15lbl.pdf
   Google Scholar
• Stalevo® (carbidopa, levodopa and entacapone) Tablets [prescribing information]. East Hanover, NJ: Novartis Pharmacy Corporation. 2010. [cited 2023 Mar 10]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021485s20lbl.pdf
   Google Scholar
• Ongentys (opicapone) capusles [prescribing information]. San Diego, CA: Neurocrine Biosciences, Inc; 2020. [cited 2023 Jan 30]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf
   Google Scholar
• Rocha JF, Santos A, Falcao A, et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol. 2014 Mar;70(3):279–286.
   PubMed Web of Science ®Google Scholar
• Castro Caldas A, Teodoro T, Ferreira JJ. The launch of opicapone for Parkinson’s disease: negatives versus positives. Expert Opin Drug Saf. 2018 Mar;17(3):331–337. doi: 10.1080/14740338.2018.1433659
   PubMed Web of Science ®Google Scholar
• Jackson GG, Muldoon RL, Akers LW. Serological Evidence for Prevention of Influenzal Infection in Volunteers by an Anti-Influenzal Drug Adamantanamine Hydrochloride. Antimicrob Agents Chemother (Bethesda). 1963;161:703–707.
   PubMedGoogle Scholar
• Wendel HA, Snyder MT, Pell S. Trial of amantadine in epidemic influenza. Clin Pharmacol Ther. 1966 Jan;7(1):38–43. doi: 10.1002/cpt19667138
   PubMed Web of Science ®Google Scholar
• Togo Y, Hornick RB, Dawkins AT Jr. Studies on induced influenza in man. I. Double-blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against a2/Rockville/1/65 strain. JAMA. 1968 Mar 25;203(13):1089–1094. doi: 10.1001/jama.1968.03140130001001
   PubMed Web of Science ®Google Scholar
• Schwab RS, England AC Jr., Poskanzer DC, et al. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969 May 19;208(7):1168–1170. DOI:10.1001/jama.1969.03160070046011
   PubMed Web of Science ®Google Scholar
• Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet. 2002 May 4;359(9317):1589–1598. DOI:10.1016/S0140-6736(02)08520-3
   PubMed Web of Science ®Google Scholar
• Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol. 2021 Dec;20(12):1048–1056. doi: 10.1016/S1474-4422(21)00249-0
   PubMed Web of Science ®Google Scholar
• Danysz W, Dekundy A, Scheschonka A, et al. Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials. J Neural Transm (Vienna). 2021 Feb;128(2):127–169.
   PubMed Web of Science ®Google Scholar
• Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson’s disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology. 1975 Jul;25(7):603–606. doi: 10.1212/WNL.25.7.603
   PubMed Web of Science ®Google Scholar
• Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson’s disease. Cochrane Database Syst Rev. 2003;2003(1):CD003468. doi:10.1002/14651858.CD003468.
   PubMedGoogle Scholar
• Bauer RB, McHenry JT. Comparison of amantadine, placebo, and levodopa in Parkinson’s disease. Neurology. 1974 Aug;24(8):715–720. doi: 10.1212/WNL.24.8.715
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Bormann J, Hubers M, et al. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991 Apr 25;206(4):297–300. DOI:10.1016/0922-4106(91)90113-V
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Bormann J, Retz W, et al. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol. 1989 Aug 3;166(3):589–590. DOI:10.1016/0014-2999(89)90384-1
   PubMed Web of Science ®Google Scholar
• Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999 Nov;56(11):1383–1386.
   PubMedGoogle Scholar
• Snow BJ, Macdonald L, McAuley D, et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled study. Clin Neuropharmacol. 2000 Mar;23(2):82–85.
   PubMed Web of Science ®Google Scholar
• Luginger E, Wenning GK, Bosch S, et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Mov Disord. 2000 Sep;15(5):873–878.
   PubMed Web of Science ®Google Scholar
• SYMMETREL® (Amantadine Hydrochloride, USP) Tablets and Syrup [prescribing information]. Chadds Ford, PA: Endo Pharmaceuticals, Inc., 2002. [cited 2023 Jan 23]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/016023_S037_SYMMETREL%20SYRUP%20AND%20TABLETS_PRNTLBL.pdf
   Google Scholar
• Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988 Jan;14(1):35–51. doi: 10.2165/00003088-198814010-00003
   PubMed Web of Science ®Google Scholar
• Horadam VW, Sharp JG, Smilack JD, et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med. 1981 Apr;94(4 pt 1):454–458.
   PubMed Web of Science ®Google Scholar
• GOCOVRI TM (amantadine) extended release capsules [prescribing information]. Emeryville, CA: Adamas Pharma LLC; 2021. [cited 2023 Jan 23]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208944lbl.pdf
   Google Scholar
• Hauser RA, Pahwa R, Wargin WA, et al. Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clin Pharmacokinet. 2019 Jan;58(1):77–88.
   PubMed Web of Science ®Google Scholar
• Devries T, Dentiste A, Handiwala L, et al. Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: results from Three Randomized, Crossover, Open-Label, Phase 1 Studies. Neurol Ther. 2019;8(2):449–460. DOI:10.1007/s40120-019-0144-1
   PubMed Web of Science ®Google Scholar
• Walker JE, Albers JW, Tourtellotte WW, et al. A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson’s disease. J Chronic Dis. 1972 Mar;25(3):149–182.
   PubMedGoogle Scholar
• Walker JE, Potvin A, Tourtellotte W, et al. Amantadine and levodopa in the treatment of Parkinson’s disease. Clin Pharmacol Ther. 1972 Jan;13(1):28–36.
   PubMed Web of Science ®Google Scholar
• Savery F. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson’s disease. Dis Nerv Syst. 1977 Aug;38(8):605–608.
   PubMedGoogle Scholar
• Kong M, Ba M, Ren C, et al. An updated meta-analysis of amantadine for treating dyskinesia in Parkinson’s disease. Oncotarget. 2017 Aug 22;8(34):57316–57326. DOI:10.18632/oncotarget.17622
   PubMedGoogle Scholar
• Collins LE, Galtieri DJ, Collins P, et al. Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: effects on locomotor activity. Behav Brain Res. 2010 Aug 25;211(2):148–155. DOI:10.1016/j.bbr.2010.03.003
   PubMed Web of Science ®Google Scholar
• Bennett KA, Tehan B, Lebon G, et al. Pharmacology and structure of isolated conformations of the adenosine A(2)A receptor define ligand efficacy. Mol Pharmacol. 2013 May;83(5):949–958.
   PubMed Web of Science ®Google Scholar
• Perez V, Sosti V, Rubio A, et al. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration. Eur J Pharmacol. 2007 Dec 8;576(1–3):83–90. DOI:10.1016/j.ejphar.2007.08.024
   PubMed Web of Science ®Google Scholar
• NOURIANZ™ (istradefylline) tablets [prescribing information]. Bedminster, NJ: Kyowa Kirin, Inc.; 2020. [cited 2023 Jan 20]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf
   Google Scholar
• Mukai M, Uchimura T, Zhang X, et al. Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects. J Clin Pharmacol. 2018 Feb;58(2):193–201.
   PubMed Web of Science ®Google Scholar